Calyxt, Inc. (NASDAQ:CLXT) has received a consensus broker rating score of 1.67 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.

Brokers have set a 12-month consensus price target of $20.67 for the company, according to Zacks. Zacks has also assigned Calyxt an industry rank of 182 out of 265 based on the ratings given to related companies.

Several brokerages recently commented on CLXT. Citigroup Inc. cut Calyxt from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 27th. Wells Fargo & Company boosted their price target on Calyxt from $17.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, September 29th. Finally, Jefferies Group LLC began coverage on Calyxt in a research report on Monday, August 14th. They set a “buy” rating and a $16.00 price target for the company.

Calyxt (NASDAQ:CLXT) traded up 1.08% during midday trading on Thursday, reaching $26.11. 9,652 shares of the company traded hands. The firm has a 50-day moving average of $20.95 and a 200-day moving average of $18.26. The stock’s market capitalization is $511.76 million. Calyxt has a 1-year low of $9.26 and a 1-year high of $29.45.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

Calyxt Company Profile

Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.

Get a free copy of the Zacks research report on Calyxt (CLXT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Calyxt Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt Inc. and related companies with's FREE daily email newsletter.